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Background: Surfactant replacement therapy (SRT) is an integral part of management of
preterm surfactant deficiency respiratory distress syndrome (RDS). Its role in the manage-
ment of RDS has been extensively studied. However, its efficacy in the management of
lung disease in preterm infants born with intrauterine growth restriction (IUGR) has not
been systematically studied.
Objective:To evaluate the efficacy of exogenous SRT in the management of preterm IUGR
lung disease.
Methods: A systematic search of all available randomized clinical trials (RCT) of SRT in
preterm IUGR infants was done according to the standard Cochrane collaboration search
strategy. Neonatal respiratory outcomes were compared between the preterm IUGR and
appropriately grown for gestational age (AGA) preterm infant populations in eligible studies.
Results:No study was identified which evaluated the efficacy or responsiveness of exoge-
nous SRT in preterm IUGR infants as compared to preterm AGA-infants. The only study
identified through the search strategy used small for gestational age (SGA; defined as less
than tenth centile for birth weight) as a proxy for IUGR. The RCT evaluated the efficacy
or responsiveness of SRT in preterm SGA group as compared to AGA-infants. The rate of
intubation, severity of RDS, rate of surfactant administration, pulmonary air leaks, and days
on the ventilator did not differ between both groups. However, the requirement for pro-
longed nasal continuous positive airway pressure (p<0.001), supplemental oxygen therapy
(p<0.01), and the incidence of bronchopulmonary dysplasia at 28 days and 36 weeks (both
p<0.01) was greater in SGA-infants.
Discussion:There is currently insufficient data available to evaluate the efficacy of SRT in
preterm IUGR lung disease. A variety of research strategies will be needed to enhance our
understanding of the role and rationale for use of SRT in preterm IUGR lung disease.
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INTRODUCTION
Introduction of surfactant replacement therapy (SRT) in the
1990s marked the beginning of a new era in the management
of prematurity-related surfactant deficiency and its clinical seque-
lae, respiratory distress syndrome (RDS) (1). Today, SRT, along
with antenatal glucocorticoid therapy, are recognized as the prin-
cipal interventions that decrease the overall mortality in preterm
infants. Further, the rationale for treatment is well supported by
robust scientific evidence (2, 3). SRT reduces the inspired oxy-
gen and ventilation requirements of the neonate, as well as the
incidence of severe RDS, pneumothorax, pulmonary interstitial
emphysema, and death (4, 5). Refinements in treatment strate-
gies, including timing of surfactant therapy, choice of preparation,
number of doses, and techniques for administration have been
established (6, 7).
Intrauterine growth restriction and prematurity are two impor-
tant pregnancy complications that lead to high rates of mortality
and morbidity in neonates. Unfortunately, they also commonly
co-exist, and thereby potentiate the risk of adverse outcomes (8).
Intrauterine growth restriction (IUGR) complicates 10–25% of
preterm births and its incidence increases with decreasing gesta-
tional age at delivery (9–11). Abnormal intrauterine cardiovas-
cular, neuroendocrine, metabolic, and oxidative stress states in
growth-restricted infants make them susceptible to both short-
and long-term complications (12). Compared to appropriately
grown age-matched counterparts, IUGR babies have higher mor-
tality rates, are at significant risk for reduced postnatal growth
and development, and have increased incidence of morbidities
such as RDS, bronchopulmonary dysplasia (BPD), retinopathy of
prematurity, and necrotizing enterocolitis (13–15).
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Despite differences in postnatal sequelae for IUGR vs. normally
grown babies, current respiratory management of lung disease in
preterm IUGR infants is not different to that of preterm AGA-
infants, which includes supportive respiratory care, early initiation
of continuous positive airway pressure (CPAP), and early rescue
surfactant therapy if RDS develops or worsens.
The purpose of this review is to systematically explore the evi-
dence available for the efficacy of exogenous surfactant therapy in
the treatment of preterm IUGR lung disease. There is evidence to
suggest from animal studies that preterm IUGR lung disease may
be different to the “classical” or “modern” standard preterm lung
disease that is observed in preterm AGA-infants. To this effect, we
intend to refresh our understanding of the science behind preterm
IUGR lung disease,with emphasis on the effect of IUGR on endoge-
nous surfactant production, metabolism, and how exogenous SRT
may influence this. We aim to examine the influence of IUGR
on the pulmonary outcomes in the preterm neonate, and gener-
ate research frontiers in this relatively poorly described area of
neonatal medicine.
METHODS
For purposes of this review, studies of preterm infants diagnosed
with IUGR were included in the study group. IUGR by defini-
tion needs to have a series of prenatal weight evaluations showing
a drop in weight centiles. Generally, the observed weight is less
than tenth centile for that gestation with ultrasound Doppler evi-
dence of abnormal placental flow. The control group comprised
of preterm AGA-infants.
CRITERIA FOR CONSIDERING STUDIES FOR THE META-ANALYSIS
Eligibility
Randomized or quasi-randomized controlled clinical trials com-
paring efficacy of surfactant administration in the form of respi-
ratory outcomes of IUGR infants to outcomes in AGA-infants
<37 weeks of gestation, at risk or with established RDS were
considered for review.
Search strategy
Standard Cochrane Neonatal Review Group (CNRG) search cri-
teria were used to identify relevant studies. We searched the
Cochrane Central Register of Controlled Trials (CENTRAL, The
Cochrane Library, 2014, Issue 1), MEDLINE (MeSH terms: pul-
monary surfactant AND fetal growth restriction OR IUGR; limits:
age, newborn: publication type: clinical trial), EMBASE, CINAHL,
conference abstracts from Pediatric Academic Societies, and jour-
nal hand searching in the English language. A search was also made
on “IUGR” and “respiratory outcomes” using the same limits as
above. Two authors (Atul Malhotra and Arun Sasi) independently
conducted the search and evaluated the articles for eligibility,
methodological quality, and risk of bias.
Outcomes
Outcomes included mortality (prior to 28 days of age, discharge),
BPD (oxygen requirement at 28 days of age, 36 weeks post men-
strual age), death or BPD (prior to 28 days, 36 weeks post men-
strual age), duration of ventilation, and duration supplemental
oxygen use. Secondary outcomes included air leaks, pulmonary
hemorrhage, culture proven sepsis, patent ductus arteriosus, intra-
ventricular hemorrhage, periventricular leukomalacia, retinopa-
thy of prematurity, necrotizing enterocolitis, and days of hospital
stay.
Data collection and analysis
Data collection was done using the standard methods of the
CNRG. For each trial, information was extracted regarding
method of randomization, allocation concealment strategies, and
completeness of reporting. The data were analyzed using RevMan5
(v5.2 2014, Copenhagen; The Nordic Cochrane Center, Cochrane
Collaboration 2012).
RESULTS
The preliminary MEDLINE search (IUGR and surfactant) yielded
a total of 48 studies as per the search criteria. A repeat search (IUGR
and respiratory outcomes) yielded 59 studies. Following a detailed
inspection of each of these studies, no studies were identified,
which evaluated the efficacy or responsiveness of exogenous SRT
in preterm IUGR infants as compared to preterm AGA-infants.
The only clinical trial randomized clinical trials (RCT) (16) iden-
tified using the above search strategy evaluated the efficacy or
responsiveness of SRT in the preterm small for gestational age
(SGA) using SGA as a proxy for IUGR. Further examination in
other search portals did not reveal additional studies and hence a
meta-analysis could not be undertaken.
The included study itself was part of a randomized multicen-
tre trial on timing of bovine surfactant therapy (17); SGA-infants
were classified as infants weighing below the tenth percentile at
birth and were compared to AGA-infants in terms of prenatal
and neonatal characteristics and neonatal outcomes. A total of
317 infants were enrolled, 59 SGA- and 258 AGA-infants. Both
groups did not differ in gestational age; however,SGA-infants had a
lower birth weight (p< 0.001). Preterm premature rupture of fetal
membranes was observed more frequently in AGA-, preeclampsia
in SGA-infants. The rate of intubation, severity of RDS, rate of
surfactant administration, pulmonary air leaks, and days on the
ventilator did not differ between both groups. However, prolonged
nasal CPAP (0 vs. 2 days, p< 0.001), supplemental oxygen ther-
apy (3 vs. 6 days, p< 0.01), and BPD at 28 days (20.2 vs. 37.3%,
p< 0.01) and 36 weeks (4.2 vs. 13.6%, p< 0.01) was diagnosed
more often in SGA-infants. Furthermore neonatal mortality (0.8
vs. 10.2%, p< 0.0001) was significantly higher in SGA-infants.
The overall RCT from which the sub-group analysis was con-
ducted for the included study had adequate random sequence
generation, allocation concealment. Further analysis was not
conducted given the lack of any other relevant studies.
DISCUSSION
The review was conducted to systematically evaluate the effect
of exogenous surfactant on preterm IUGR lung disease. We could
find no suitable preterm IUGR study for this evaluation and hence
a meta-analysis and inference cannot be made based on available
evidence. The only relevant study included infants who were SGA
at birth, not those who were diagnosed as IUGR. This highlights an
important issue with literature on this subject and a lack of stan-
dard definitions. SGA describes small infants, <10% centile for
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birth weight, but these infants may be otherwise well but consti-
tutionally small. Whereas, IUGR is generally characterized by the
presence of serial evaluations of falling fetal growth, commonly
characterized by descriptive indices of <10% centile for weight at
particular gestation and abnormal umbilical Doppler ultrasound.
Clear definitions are not always provided in published work, and
some studies on IUGR infants may be simply called SGA, and
vice versa.
We present the current understanding of preterm IUGR lung
disease first and then discuss the role of exogenous surfactant.
PRETERM LUNG DISEASE IN GROWTH-RESTRICTED INFANTS
Preterm infants with IUGR have a high risk of pulmonary mor-
bidities including long-term alterations in respiratory function
(18–20), however, the effect of IUGR on incidence and severity of
RDS is still debatable. It is important to reflect on the diagnosis of
RDS in this era of wide-spread antenatal steroid use and early non-
invasive respiratory support. Unless there is chest X-ray evidence
of RDS, the diagnosis of RDS in every preterm infant with distress,
and especially in an IUGR infant, may be fraught with error and
misdiagnosis. The perceived notion of accelerated lung matura-
tion and, hence, reduced incidence and severity of RDS in IUGR
infants are refuted by a number of studies (21–23). McIntire and
co-workers reported an increasing incidence of RDS with decreas-
ing birth weight centiles, at any given gestational age. Infants born
at ≤25 weeks gestation had a higher incidence of RDS compared
to heavier infants at all gestational ages between 28 to 37 weeks
(22). Spinillo et al. similarly reported a significantly increased risk
of RDS in infants born between 24 to 31 weeks gestation with
IUGR (24). Several underlying mechanisms have been postulated
to explain this increased incidence of RDS in IUGR infants, such
as reduced or impaired surfactant release or diminished response
to glucocorticoids (12).
An additional concern for IUGR infants is the observed asso-
ciation between IUGR and BPD (13, 25, 26). BPD may occur
as a consequence of high levels of oxygen or prolonged use of
invasive ventilation, wherein the still relatively immature lungs
become damaged and normal lung development is interrupted.
Compared to AGA-infants, growth-restricted newborns have a
three to fourfold increase in oxygen dependency at 36 weeks
postmenstrual age (26). It is however poorly understood why
IUGR infants have high rates of BPD compared to their AGA
counterparts. It may be hypothesized that the underlying sus-
ceptibility for BPD in IUGR babies reflects a continuum of
adverse events affecting lung development, with its origins in fetal
life (27).
In utero, IUGR fetuses must adapt to chronic hypoxia to sur-
vive. One key adaptation is the redistribution of cardiac output to
preferentially provide blood flow and oxygen supply to the brain
and heart, commonly referred to as “brain-sparing.” While this
response may assist survival in utero, it necessitates reduced oxy-
gen supply to other organs during development, including the
lungs (28, 29). In experimental sheep studies of IUGR fetuses and
offspring, growth restriction induced abnormal lung structure and
functional deficits in gas exchange, and reduced lung compliance,
and these functional lung deficits persisted to adolescence (30,
31). It is, however, not known whether basic lung developmental
alterations underlie the vulnerability of the IUGR infant to BPD,
particularly with the knowledge that IUGR is also associated with
a variety of metabolic, cardiovascular, and endocrine dysfunctions
that could in turn lead to oxygen free radical and inflammatory
imbalance, reperfusion injury, and therefore more severe or greater
susceptibility to early neonatal lung disease (31–33).
EFFECT OF IUGR ON ENDOGENOUS SURFACTANT
Understanding the basic physiology of the IUGR lung, and dif-
ferences with control lungs in relation to endogenous surfactant
is required to appreciate potential differences in the requirement
and/or response to exogenous surfactants. The scientific data for
the effect of IUGR on endogenous surfactant production and func-
tion is sparse and conflicting. Whereas some experimental studies
in animal models reported significant alteration in maturation
of Type II pneumocytes resulting in reduced surfactant content
and activity others have reported a significant increase in surfac-
tant protein synthesis (34, 35). Furthermore, chronic hypoxia and
acidosis associated with IUGR may attenuate surfactant synthesis
(27). In a sheep model of IUGR induced by placental embolization
from 120 to 140 days gestation, Cock et al. did not demonstrate
any alteration in surfactant protein mRNA expression of SP-A,
B, or C in lung tissue at term (36). In contrast, Gagnon et al.
reported increased lung tissue SP-A and SP-B mRNA expression,
and that the increase was closely associated with plasma cortisol
levels. Chronic fetal growth restriction from conception in carun-
clectomised sheep showed decreased lung tissue mRNA expression
of SP-A, B, and C at 133 and 141 days gestation, with an inverse
relationship between plasma cortisol concentration and SP-A and
B expression (37). In contrast, IUGR induced by single umbilical
artery ligation in sheep fetuses from 108 days gestation had no
effect on lung tissue surfactant mRNA levels by 115 days gesta-
tion, nor did it alter alveolarisation (38). In addition to observed
alterations in surfactant protein synthesis, fetal growth restric-
tion could also affect the lipid components of surfactant. For
example, growth-restricted rats are shown to have significantly
reduced phosphatidylcholine content, lower lung volume, and
reduced alveolar air spaces (39). Importantly, none of these studies
have looked at levels of surfactant protein in the airways (e.g., in
bronchoalveolar lavage fluid), the composition of the surfactant
produced, the number of lamellar bodies within the type 2 alveolar
epithelial cells, or the ability of surfactant release from the lamellar
bodies (surfactant availability). These experimental observations,
when available, would assist in understanding surfactant release,
turnover, and metabolism at the alveolar level in IUGR and AGA
fetuses.
EXOGENOUS SURFACTANT IN GROWTH-RESTRICTED PRETERM LUNG
DISEASE
We did not identify any studies that evaluated surfactant response
in preterm IUGR infants. One study evaluated the responsiveness
to surfactant therapy in preterm SGA-infants, as discussed above.
The outcomes in this preterm SGA cohort were different as com-
pared to the AGA group, but reflected more chronic outcomes
such as oxygen use, BPD, mortality, and length of stay as com-
pared to acute outcomes (days of ventilation, pulmonary air leaks,
pulmonary hemorrhage, and IVH). Whilst studies have shown
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superior benefits of surfactant therapy in a sub-group of prema-
ture infants <1000 g, there are no studies that have specifically
looked at the effectiveness of surfactant therapy in IUGR infants
alone (3–5). As described above, whether there is a strong asso-
ciation between preterm lung disease and elevated risk in IUGR
infants has not yet been conclusively described, and there are not
yet definitive animal studies in appropriate IUGR models. But,
there are now strong indications that pulmonary function and
structure in preterm IUGR infants appear quite different com-
pared to appropriately grown babies. With this in mind it should
be queried whether the management strategy of treating all RDS
infants with a blanket approach is best-practice. Alterations in
basic morphology, lung maturation, and/or pulmonary surfactant
functions induced by fetal growth restriction would be expected to
influence the effectiveness of exogenous surfactant when admin-
istered to IUGR preterm infants. Considering the demonstrated
impact of growth restriction on the immature lung, it is logical
to hypothesize that exogenous surfactant responsiveness as well as
the ideal dose; number of doses etc. might be different in IUGR
compared to AGA babies. Furthermore, such treatment may be
influenced by the degree of growth restriction.
Indeed, most studies related to surfactant use in preterm infants
have not reported a sub-group analysis on the effectiveness of
surfactant therapy in IUGR infants (3, 4). The relatively small
numbers of IUGR infants with the potential to be recruited into
a larger study significantly impacts the availability of data for this
sub-group. However, it is interesting, and perhaps unfortunate that
the animal literature is also sparse in terms of information on the
effect of postnatal surfactant administration in IUGR newborns
(20, 22). There is some indirect experimental data that alludes to
the effects of surfactant on IUGR lungs, using analysis of tissue
surfactant content but even these results are conflicting, and are
dependent upon the species, the method used to induce IUGR,
and the timing of the study. In a rat model of IUGR induced by
bilateral uterine artery ligation, growth restriction is associated
with significantly reduced surfactant apo-protein A-D levels (40).
Contrary to this, a study in humans by Brianna et al. demon-
strated increased circulating levels of surfactant protein D (SP-D)
on postnatal day 1 and 4 (41). The authors suggest that higher SP-
D concentration may reflect the relative immaturity of the lung
and leaky alveolar-capillary membrane. It has also been shown
that both exogenous and endogenous surfactant can be inacti-
vated by a number of factors such as serum proteins, hemoglobin,
and meconium (42, 43). In vitro studies show that addition of
serum to the sub-phase, or mixing serum with surfactant reduces
the surface activity of surfactants (44). In excised rat lungs, or in
live rats, introduction of serum proteins into the trachea causes
changes in mechanical behavior of the lungs consistent with sur-
factant inactivation (45). Inactivation of surfactant by capillary to
alveolar leak of serum is implicated in the pathogenesis of acute
lung injury (46). Akin to acute lung injury, structural immaturity
of lungs in the IUGR fetus leading to leaky capillary beds could
in turn have a direct effect on surfactant deactivation. Presently,
this cannot be supported or refuted with respect to the IUGR
infant from the available literature, but this may represent another
causal mechanism of lung injury and disease in IUGR infants that
requires investigation.
RESEARCH IMPLICATIONS
The efficacy of exogenous surfactant administration in preterm
IUGR infants currently represents a significant knowledge gap in
neonatal research and clinical practice. There is little evidence on
the effectiveness of exogenous surfactant therapy in preterm IUGR
infants, primarily due to the relatively low numbers of such infants
born into NICUs, and the tendency in published studies to group
IUGR preterm infants with their appropriately grown counter-
parts. Because of this, current neonatal practice of the respiratory
management of preterm IUGR infants is based on the evidence
that RDS may be similar or greater in these infants as compared to
AGA preterm infants. Given the ethical implications of withhold-
ing surfactant therapy from preterm IUGR infants who display
features of RDS, there is a real need to turn to appropriate ani-
mal models to study efficacy of SRT. In the first instance, a greater
understanding of the consequences of IUGR on surfactant produc-
tion, release, and turnover will help guide future directions in the
administration of exogenous surfactant therapy for these infants.
The next step should be a systematic evaluation of the effects of
exogenous SRT on the surfactant pool and its effect on the phys-
iological characteristics of pulmonary function. In the future, it
would be appropriate for clinical trials of surfactant replacement
to address different time points, frequency, type, and nature of
surfactant replacement specifically in the preterm IUGR infant
population.
CONCLUSION
There is insufficient data to conclude on the efficacy of SRT in
management of preterm IUGR lung disease. There is strong clini-
cal and experimental data to indicate that IUGR adversely affects
lung maturation, lung function, surfactant production, and its
composition in preterm neonates. There is a need for basic, as
well as translational research in this area to further understand the
dynamics of surfactant synthesis and function in preterm infants
with IUGR to enable us to optimize respiratory care in them.
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